AbbVie Has 2Q Beat Helped By Skyrizi and Rinvoq -- Market Talk
Dow Jones2026/07/31 13:340933 ET - AbbVie reports 2Q results ahead of expectations, JPMorgan analysts say in a research note. The top-line beat was fairly broad based, with Both Skyrizi and Rinvoq modestly ahead of estimates. "On the call, we will be closely listening for any updated expectations on 1) uptake of Skyrizi/Rinvoq (and updated guidance for both) and 2) business development commentary," the analysts say. AbbVie is off 1% in early trading, after lowering its full-year adjusted earnings outlook to account for its acquisition of Apogee Therapeutics. (connor.hart@wsj.com)
(END) Dow Jones Newswires
July 31, 2026 09:34 ET (13:34 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
NZD/USD Price Forecast: Bulls eye 0.6000 after SMA break
Puma Exploration FY26 Q1 net loss narrows to CAD 206,664
Kingsway CEO John Taylor Maloney Fitzgerald acquires 278 common shares valued at $2,496.44
Crypto prices
More
